Comparative pharmacokinetic study for linezolid and two novel antibacterial oxazolidinone derivatives in rabbits

Can differences in the pharmacokinetic properties explain the discrepancies between their in vivo and in vitro antibacterial activities?

Mohsen A. Hedaya, Vidhya Thomas, Mohamed E. Abdel-Hamid, Elijah Kehinde, Oludotun A. Phillips

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This is a comparative pharmacokinetics study of linezolid (Lzd), and two novel oxazolidinone antibacterial agents—PH027 and PH051—in rabbits to determine if the discrepancy between the in vitro and in vivo activities of the novel compounds is due to pharmacokinetic factors. The pharmacokinetics after IV and oral administration, plasma protein binding and tissue distribution for the three compounds were compared. The elimination half-lives were 52.4 _ 6.3, 68.7 _ 12.1 and 175 _ 46.1 min for Lzd, PH027 and PH051, respectively. The oral bioavailability for Lzd, PH027 and PH051 administered as suspension were 38.7%, 22.1% and 4.73%, which increased significantly when administered as microemulsion to 51.7%, 72.9% and 13.9%. The plasma protein binding were 32-34%, 37-38% and 90-91% for Lzd, PH027 and PH051. The tissue distribution for PH027 and PH051 in all investigated tissues were higher than that for Lzd. It can be concluded that the lower bioavailability of PH027 and PH051 compared to Lzd when administered as suspension is the main cause of their lower in vivo activity, despite their comparable in vitro activity. Differences in the other pharmacokinetic characteristics cannot explain the lower in vivo activity. The in vivo activity of the novel compounds should be re-evaluated using formulations with good oral bioavailability.

Original languageEnglish
Article number34
JournalPharmaceutics
Volume9
Issue number3
DOIs
Publication statusPublished - Sep 7 2017

Fingerprint

Linezolid
Oxazolidinones
Pharmacokinetics
Rabbits
Biological Availability
Tissue Distribution
Protein Binding
Blood Proteins
Suspensions
Oral Administration
In Vitro Techniques

Keywords

  • Bioavailability
  • Linezolid
  • Microemulsion
  • Oxazolidinone antibiotics
  • Pharmacokinetics
  • Renal excretion
  • Tissue distribution

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Comparative pharmacokinetic study for linezolid and two novel antibacterial oxazolidinone derivatives in rabbits : Can differences in the pharmacokinetic properties explain the discrepancies between their in vivo and in vitro antibacterial activities? / Hedaya, Mohsen A.; Thomas, Vidhya; Abdel-Hamid, Mohamed E.; Kehinde, Elijah; Phillips, Oludotun A.

In: Pharmaceutics, Vol. 9, No. 3, 34, 07.09.2017.

Research output: Contribution to journalArticle

@article{c6e2709e899d438cacb90a9eba24fdaf,
title = "Comparative pharmacokinetic study for linezolid and two novel antibacterial oxazolidinone derivatives in rabbits: Can differences in the pharmacokinetic properties explain the discrepancies between their in vivo and in vitro antibacterial activities?",
abstract = "This is a comparative pharmacokinetics study of linezolid (Lzd), and two novel oxazolidinone antibacterial agents—PH027 and PH051—in rabbits to determine if the discrepancy between the in vitro and in vivo activities of the novel compounds is due to pharmacokinetic factors. The pharmacokinetics after IV and oral administration, plasma protein binding and tissue distribution for the three compounds were compared. The elimination half-lives were 52.4 _ 6.3, 68.7 _ 12.1 and 175 _ 46.1 min for Lzd, PH027 and PH051, respectively. The oral bioavailability for Lzd, PH027 and PH051 administered as suspension were 38.7{\%}, 22.1{\%} and 4.73{\%}, which increased significantly when administered as microemulsion to 51.7{\%}, 72.9{\%} and 13.9{\%}. The plasma protein binding were 32-34{\%}, 37-38{\%} and 90-91{\%} for Lzd, PH027 and PH051. The tissue distribution for PH027 and PH051 in all investigated tissues were higher than that for Lzd. It can be concluded that the lower bioavailability of PH027 and PH051 compared to Lzd when administered as suspension is the main cause of their lower in vivo activity, despite their comparable in vitro activity. Differences in the other pharmacokinetic characteristics cannot explain the lower in vivo activity. The in vivo activity of the novel compounds should be re-evaluated using formulations with good oral bioavailability.",
keywords = "Bioavailability, Linezolid, Microemulsion, Oxazolidinone antibiotics, Pharmacokinetics, Renal excretion, Tissue distribution",
author = "Hedaya, {Mohsen A.} and Vidhya Thomas and Abdel-Hamid, {Mohamed E.} and Elijah Kehinde and Phillips, {Oludotun A.}",
year = "2017",
month = "9",
day = "7",
doi = "10.3390/pharmaceutics9030034",
language = "English",
volume = "9",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Comparative pharmacokinetic study for linezolid and two novel antibacterial oxazolidinone derivatives in rabbits

T2 - Can differences in the pharmacokinetic properties explain the discrepancies between their in vivo and in vitro antibacterial activities?

AU - Hedaya, Mohsen A.

AU - Thomas, Vidhya

AU - Abdel-Hamid, Mohamed E.

AU - Kehinde, Elijah

AU - Phillips, Oludotun A.

PY - 2017/9/7

Y1 - 2017/9/7

N2 - This is a comparative pharmacokinetics study of linezolid (Lzd), and two novel oxazolidinone antibacterial agents—PH027 and PH051—in rabbits to determine if the discrepancy between the in vitro and in vivo activities of the novel compounds is due to pharmacokinetic factors. The pharmacokinetics after IV and oral administration, plasma protein binding and tissue distribution for the three compounds were compared. The elimination half-lives were 52.4 _ 6.3, 68.7 _ 12.1 and 175 _ 46.1 min for Lzd, PH027 and PH051, respectively. The oral bioavailability for Lzd, PH027 and PH051 administered as suspension were 38.7%, 22.1% and 4.73%, which increased significantly when administered as microemulsion to 51.7%, 72.9% and 13.9%. The plasma protein binding were 32-34%, 37-38% and 90-91% for Lzd, PH027 and PH051. The tissue distribution for PH027 and PH051 in all investigated tissues were higher than that for Lzd. It can be concluded that the lower bioavailability of PH027 and PH051 compared to Lzd when administered as suspension is the main cause of their lower in vivo activity, despite their comparable in vitro activity. Differences in the other pharmacokinetic characteristics cannot explain the lower in vivo activity. The in vivo activity of the novel compounds should be re-evaluated using formulations with good oral bioavailability.

AB - This is a comparative pharmacokinetics study of linezolid (Lzd), and two novel oxazolidinone antibacterial agents—PH027 and PH051—in rabbits to determine if the discrepancy between the in vitro and in vivo activities of the novel compounds is due to pharmacokinetic factors. The pharmacokinetics after IV and oral administration, plasma protein binding and tissue distribution for the three compounds were compared. The elimination half-lives were 52.4 _ 6.3, 68.7 _ 12.1 and 175 _ 46.1 min for Lzd, PH027 and PH051, respectively. The oral bioavailability for Lzd, PH027 and PH051 administered as suspension were 38.7%, 22.1% and 4.73%, which increased significantly when administered as microemulsion to 51.7%, 72.9% and 13.9%. The plasma protein binding were 32-34%, 37-38% and 90-91% for Lzd, PH027 and PH051. The tissue distribution for PH027 and PH051 in all investigated tissues were higher than that for Lzd. It can be concluded that the lower bioavailability of PH027 and PH051 compared to Lzd when administered as suspension is the main cause of their lower in vivo activity, despite their comparable in vitro activity. Differences in the other pharmacokinetic characteristics cannot explain the lower in vivo activity. The in vivo activity of the novel compounds should be re-evaluated using formulations with good oral bioavailability.

KW - Bioavailability

KW - Linezolid

KW - Microemulsion

KW - Oxazolidinone antibiotics

KW - Pharmacokinetics

KW - Renal excretion

KW - Tissue distribution

UR - http://www.scopus.com/inward/record.url?scp=85029725391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029725391&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics9030034

DO - 10.3390/pharmaceutics9030034

M3 - Article

VL - 9

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 3

M1 - 34

ER -